Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Guardant Health, Inc.GH · Entity 3238 | Director · Co-Chief Executive Officer | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Guardant Health, Inc.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,827,168 |
Reported balance
After 2026-09-30 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-09-30 · Exercise / conversion · Acquired 2,817 · Balance 1,827,168 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,825,740 |
Reported balance
After 2026-09-30 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-09-30 · Tax withholding · Disposed 1,428 · Balance 1,825,740 F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. |
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,849,737 |
Reported balance
After 2026-10-01 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-10-01 · Exercise / conversion · Acquired 23,997 · Balance 1,849,737 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,859,453 |
Reported balance
After 2026-10-01 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-10-01 · Exercise / conversion · Acquired 9,716 · Balance 1,859,453 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,842,366 |
Reported balance
After 2026-10-01 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2026-10-01 · Tax withholding · Disposed 17,087 · Balance 1,842,366 F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 2,817 |
Reported balance
After 2026-09-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-30 · Exercise / conversion · Disposed 2,817 · Balance 2,817 F2: This represents a restricted stock unit award granted on March 17, 2026 that vests in four equal installments on the last day of each calendar quarter, March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 23,998 |
Reported balance
After 2026-10-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-10-01 · Exercise / conversion · Disposed 23,997 · Balance 23,998 F4: This represents a restricted stock unit award granted on March 18, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 48,580 |
Reported balance
After 2026-10-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-10-01 · Exercise / conversion · Disposed 9,716 · Balance 48,580 F5: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.
F2: This represents a restricted stock unit award granted on March 17, 2026 that vests in four equal installments on the last day of each calendar quarter, March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026.
F3: Not applicable for Restricted Stock Units.
F4: This represents a restricted stock unit award granted on March 18, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
F5: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 24, 2019 Filed Apr 26, 2019 00:12 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 4,015 | $66.38 | $266,515.70 |
DisclosureSEC source: 0001628280-19-004762 · wf-form4_155623750501525.xml · nonDerivative · entry 25 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,869 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F24 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.87 to $66.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 24, 2019 Filed Apr 26, 2019 00:12 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 3,008 | $65.30 | $196,422.40 |
DisclosureSEC source: 0001628280-19-004762 · wf-form4_155623750501525.xml · nonDerivative · entry 24 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,884 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F23 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.86 to $65.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 24, 2019 Filed Apr 26, 2019 00:12 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 7,454 | $4.18 | $31,157.72 |
DisclosureSEC source: 0001628280-19-004762 · wf-form4_155623750501525.xml · nonDerivative · entry 23 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,892 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · shares: The shares were acquired and then sold contemporaneously upon the cashless exercise of stock option at an exercise price of $4.18 per share. Read SEC document |
| April 24, 2019 Filed Apr 26, 2019 00:12 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 100 | $67.22 | $6,722.00 |
DisclosureSEC source: 0001628280-19-004762 · wf-form4_155623750501525.xml · nonDerivative · entry 22 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Sana Talasaz 2018 Irrevocable Trust Disclosed balance after: 13,333 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| April 24, 2019 Filed Apr 26, 2019 00:12 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,869 | $66.45 | $190,645.05 |
DisclosureSEC source: 0001628280-19-004762 · wf-form4_155623750501525.xml · nonDerivative · entry 21 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Sana Talasaz 2018 Irrevocable Trust Disclosed balance after: 13,433 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F22 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.96 to $66.9, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 24, 2019 Filed Apr 26, 2019 00:12 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,097 | $65.43 | $137,206.71 |
DisclosureSEC source: 0001628280-19-004762 · wf-form4_155623750501525.xml · nonDerivative · entry 20 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Sana Talasaz 2018 Irrevocable Trust Disclosed balance after: 16,302 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F21 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.96 to $65.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 24, 2019 Filed Apr 26, 2019 00:12 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 400 | $66.93 | $26,772.00 |
DisclosureSEC source: 0001628280-19-004762 · wf-form4_155623750501525.xml · nonDerivative · entry 19 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Samar Talasaz 2018 Irrevocable Trust Disclosed balance after: 13,333 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F20 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.86 to $67.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 24, 2019 Filed Apr 26, 2019 00:12 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,780 | $66.43 | $184,675.40 |
DisclosureSEC source: 0001628280-19-004762 · wf-form4_155623750501525.xml · nonDerivative · entry 18 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Samar Talasaz 2018 Irrevocable Trust Disclosed balance after: 13,733 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F19 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.86 to $66.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 24, 2019 Filed Apr 26, 2019 00:12 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,886 | $65.28 | $123,118.08 |
DisclosureSEC source: 0001628280-19-004762 · wf-form4_155623750501525.xml · nonDerivative · entry 17 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Samar Talasaz 2018 Irrevocable Trust Disclosed balance after: 16,513 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F18 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.81 to $65.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 24, 2019 Filed Apr 26, 2019 00:12 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 3,136 | $66.92 | $209,861.12 |
DisclosureSEC source: 0001628280-19-004762 · wf-form4_155623750501525.xml · nonDerivative · entry 16 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 3,745,120 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F17 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.78 to $67.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 24, 2019 Filed Apr 26, 2019 00:12 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 10,018 | $66.29 | $664,093.22 |
DisclosureSEC source: 0001628280-19-004762 · wf-form4_155623750501525.xml · nonDerivative · entry 15 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 3,748,256 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F16 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.78 to $66.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 24, 2019 Filed Apr 26, 2019 00:12 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 6,778 | $65.28 | $442,467.84 |
DisclosureSEC source: 0001628280-19-004762 · wf-form4_155623750501525.xml · nonDerivative · entry 14 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 3,758,274 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F15 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.78 to $65.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 23, 2019 Filed Apr 26, 2019 00:12 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 15,202 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001628280-19-004762 · wf-form4_155623750501525.xml · derivative · entry 28 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,139,454 Underlying: COMMON STOCK · 15,202 shares Expires 2027-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F26 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. Read SEC document |
| April 23, 2019 Filed Apr 26, 2019 00:12 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 3,240 | $67.63 | $219,121.20 |
DisclosureSEC source: 0001628280-19-004762 · wf-form4_155623750501525.xml · nonDerivative · entry 13 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,438 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F14 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $67.46 to $68.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 23, 2019 Filed Apr 26, 2019 00:12 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 11,957 | $66.92 | $800,162.44 |
DisclosureSEC source: 0001628280-19-004762 · wf-form4_155623750501525.xml · nonDerivative · entry 12 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,678 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F13 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.46 to $67.44 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 23, 2019 Filed Apr 26, 2019 00:12 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,410 | $66.17 | $93,299.70 |
DisclosureSEC source: 0001628280-19-004762 · wf-form4_155623750501525.xml · nonDerivative · entry 11 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,635 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F12 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.44 to $66.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 23, 2019 Filed Apr 26, 2019 00:12 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 15,202 | $4.18 | $63,544.36 |
DisclosureSEC source: 0001628280-19-004762 · wf-form4_155623750501525.xml · nonDerivative · entry 10 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,045 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · shares: The shares were acquired and then sold contemporaneously upon the cashless exercise of stock option at an exercise price of $4.18 per share. Read SEC document |
| April 23, 2019 Filed Apr 26, 2019 00:12 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,810 | $67.67 | $122,482.70 |
DisclosureSEC source: 0001628280-19-004762 · wf-form4_155623750501525.xml · nonDerivative · entry 9 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Sana Talasaz 2018 Irrevocable Trust Disclosed balance after: 18,399 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F10 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $67.43 to $68.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 23, 2019 Filed Apr 26, 2019 00:12 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 8,180 | $66.92 | $547,405.60 |
DisclosureSEC source: 0001628280-19-004762 · wf-form4_155623750501525.xml · nonDerivative · entry 8 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Sana Talasaz 2018 Irrevocable Trust Disclosed balance after: 20,209 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.42 to $67.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 23, 2019 Filed Apr 26, 2019 00:12 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 616 | $66.07 | $40,699.12 |
DisclosureSEC source: 0001628280-19-004762 · wf-form4_155623750501525.xml · nonDerivative · entry 7 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Sana Talasaz 2018 Irrevocable Trust Disclosed balance after: 28,389 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.41 to $66.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 23, 2019 Filed Apr 26, 2019 00:12 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,000 | $67.77 | $67,770.00 |
DisclosureSEC source: 0001628280-19-004762 · wf-form4_155623750501525.xml · nonDerivative · entry 6 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Samar Talasaz 2018 Irrevocable Trust Disclosed balance after: 18,399 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $67.67 to $68.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 23, 2019 Filed Apr 26, 2019 00:12 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 8,044 | $67.03 | $539,189.32 |
DisclosureSEC source: 0001628280-19-004762 · wf-form4_155623750501525.xml · nonDerivative · entry 5 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Samar Talasaz 2018 Irrevocable Trust Disclosed balance after: 19,399 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.67 to $67.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 23, 2019 Filed Apr 26, 2019 00:12 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,562 | $66.35 | $103,638.70 |
DisclosureSEC source: 0001628280-19-004762 · wf-form4_155623750501525.xml · nonDerivative · entry 4 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Samar Talasaz 2018 Irrevocable Trust Disclosed balance after: 27,443 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.58 to $66.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 23, 2019 Filed Apr 26, 2019 00:12 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 8,318 | $67.65 | $562,712.70 |
DisclosureSEC source: 0001628280-19-004762 · wf-form4_155623750501525.xml · nonDerivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 3,765,052 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $67.40 to $68.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 23, 2019 Filed Apr 26, 2019 00:12 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 30,710 | $66.91 | $2,054,806.10 |
DisclosureSEC source: 0001628280-19-004762 · wf-form4_155623750501525.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 3,773,370 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.40 to $67.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 23, 2019 Filed Apr 26, 2019 00:12 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,697 | $66.06 | $178,163.82 |
DisclosureSEC source: 0001628280-19-004762 · wf-form4_155623750501525.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 3,804,080 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.40 to $66.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:48 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 44,426 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001628280-19-004662 · wf-form4_155614969045425.xml · derivative · entry 27 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,154,656 Underlying: COMMON STOCK · 44,426 shares Expires 2027-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F23 · derivative.exercise_price: The exercise price of $4.17 reported in the Reporting Person's Form 3/A filed on October 11, 2018 was in error. F24 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:48 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 4,963 | $68.59 | $340,412.17 |
DisclosureSEC source: 0001628280-19-004662 · wf-form4_155614969045425.xml · nonDerivative · entry 25 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,843 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F22 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $68.00 to $68.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:48 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 6,160 | $67.27 | $414,383.20 |
DisclosureSEC source: 0001628280-19-004662 · wf-form4_155614969045425.xml · nonDerivative · entry 24 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,806 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F21 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $67.00 to $67.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:48 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 5,739 | $66.54 | $381,873.06 |
DisclosureSEC source: 0001628280-19-004662 · wf-form4_155614969045425.xml · nonDerivative · entry 23 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,966 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F12 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.00 to $66.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:48 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 10,715 | $65.39 | $700,653.85 |
DisclosureSEC source: 0001628280-19-004662 · wf-form4_155614969045425.xml · nonDerivative · entry 22 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,705 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F11 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.00 to $65.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:48 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 16,312 | $64.36 | $1,049,840.32 |
DisclosureSEC source: 0001628280-19-004662 · wf-form4_155614969045425.xml · nonDerivative · entry 21 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,420 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F20 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.00 to $64.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:48 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 4,643 | $63.91 | $296,734.13 |
DisclosureSEC source: 0001628280-19-004662 · wf-form4_155614969045425.xml · nonDerivative · entry 20 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,732 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.82 to $63.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:48 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 44,426 | $4.18 | $185,700.68 |
DisclosureSEC source: 0001628280-19-004662 · wf-form4_155614969045425.xml · nonDerivative · entry 19 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F19 · shares: The shares were acquired and then sold contemporaneously upon the cashless exercise of stock option at an exercise price of $4.18 per share. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:48 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,786 | $68.46 | $122,269.56 |
DisclosureSEC source: 0001628280-19-004662 · wf-form4_155614969045425.xml · nonDerivative · entry 18 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Sana Talasaz 2018 Irrevocable Trust Disclosed balance after: 29,005 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F18 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $68.00 to $68.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:48 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 5,504 | $67.43 | $371,134.72 |
DisclosureSEC source: 0001628280-19-004662 · wf-form4_155614969045425.xml · nonDerivative · entry 17 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Sana Talasaz 2018 Irrevocable Trust Disclosed balance after: 30,791 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F17 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $67.00 to $67.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:48 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 3,070 | $66.61 | $204,492.70 |
DisclosureSEC source: 0001628280-19-004662 · wf-form4_155614969045425.xml · nonDerivative · entry 16 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Sana Talasaz 2018 Irrevocable Trust Disclosed balance after: 36,295 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F16 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.02 to $66.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:48 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 7,187 | $65.54 | $471,035.98 |
DisclosureSEC source: 0001628280-19-004662 · wf-form4_155614969045425.xml · nonDerivative · entry 15 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Sana Talasaz 2018 Irrevocable Trust Disclosed balance after: 39,365 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F15 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.00 to $65.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:48 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 9,902 | $64.42 | $637,886.84 |
DisclosureSEC source: 0001628280-19-004662 · wf-form4_155614969045425.xml · nonDerivative · entry 14 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Sana Talasaz 2018 Irrevocable Trust Disclosed balance after: 46,552 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F14 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.01 to $64.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:48 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 3,546 | $63.91 | $226,624.86 |
DisclosureSEC source: 0001628280-19-004662 · wf-form4_155614969045425.xml · nonDerivative · entry 13 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Sana Talasaz 2018 Irrevocable Trust Disclosed balance after: 56,454 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.82 to $63.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: The allocation of shares among such entities reported in the Reporting Person's Form 4 filed on October 11, 2018 was in error and has been corrected in this form. F3 · ownership.nature: The allocation of shares among such entities reported in the Reporting Person's Form 4 filed on October 11, 2018 was in error and has been corrected in this form. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:48 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 70 | $68.44 | $4,790.80 |
DisclosureSEC source: 0001628280-19-004662 · wf-form4_155614969045425.xml · nonDerivative · entry 12 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Samar Talasaz 2018 Irrevocable Trust Disclosed balance after: 29,005 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:48 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 7,209 | $67.32 | $485,309.88 |
DisclosureSEC source: 0001628280-19-004662 · wf-form4_155614969045425.xml · nonDerivative · entry 11 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Samar Talasaz 2018 Irrevocable Trust Disclosed balance after: 29,075 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F13 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $67.00 to $67.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:48 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 4,630 | $66.61 | $308,404.30 |
DisclosureSEC source: 0001628280-19-004662 · wf-form4_155614969045425.xml · nonDerivative · entry 10 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Samar Talasaz 2018 Irrevocable Trust Disclosed balance after: 36,284 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F12 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.00 to $66.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:48 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 7,614 | $65.39 | $497,879.46 |
DisclosureSEC source: 0001628280-19-004662 · wf-form4_155614969045425.xml · nonDerivative · entry 9 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Samar Talasaz 2018 Irrevocable Trust Disclosed balance after: 40,914 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F11 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.00 to $65.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:48 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 7,239 | $64.44 | $466,481.16 |
DisclosureSEC source: 0001628280-19-004662 · wf-form4_155614969045425.xml · nonDerivative · entry 8 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Samar Talasaz 2018 Irrevocable Trust Disclosed balance after: 48,528 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F10 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.00 to $64.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:48 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 4,233 | $63.89 | $270,446.37 |
DisclosureSEC source: 0001628280-19-004662 · wf-form4_155614969045425.xml · nonDerivative · entry 7 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Samar Talasaz 2018 Irrevocable Trust Disclosed balance after: 55,767 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.82 to $63.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: The allocation of shares among such entities reported in the Reporting Person's Form 4 filed on October 11, 2018 was in error and has been corrected in this form. F3 · ownership.nature: The allocation of shares among such entities reported in the Reporting Person's Form 4 filed on October 11, 2018 was in error and has been corrected in this form. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:48 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 101 | $69.01 | $6,970.01 |
DisclosureSEC source: 0001628280-19-004662 · wf-form4_155614969045425.xml · nonDerivative · entry 6 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 3,806,777 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $68.90 to $69.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:48 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 9,602 | $68.26 | $655,432.52 |
DisclosureSEC source: 0001628280-19-004662 · wf-form4_155614969045425.xml · nonDerivative · entry 5 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 3,806,878 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $67.82 to $68.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:48 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 25,649 | $67.26 | $1,725,151.74 |
DisclosureSEC source: 0001628280-19-004662 · wf-form4_155614969045425.xml · nonDerivative · entry 4 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 3,816,480 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.80 to $67.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:48 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 16,594 | $66.12 | $1,097,195.28 |
DisclosureSEC source: 0001628280-19-004662 · wf-form4_155614969045425.xml · nonDerivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 3,842,129 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.80 to $66.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.